Kala Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
Revenue | $0 | $0 | $0 |
Gross Profit | -54 | -128 | |
EBITDA | -1,621 | -6,473 | |
EBIT | 827 | -6,601 | |
Net Income | -1,621 | 686 | -7,564 |
Net Change In Cash | 0 | 0 | 0 |
Free Cash Flow | -2,895 | -4,556 | -10,861 |
Cash | 1,764 | 7,557 | 21,096 |
Basic Shares | 237 | 556 | 140 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $3,892 |
Gross Profit | -317 | -259 | -303 | 1,332 |
EBITDA | -23,387 | -32,469 | -36,082 | -36,696 |
EBIT | -23,704 | -32,728 | -36,385 | -37,556 |
Net Income | -26,980 | -38,511 | -42,199 | -44,822 |
Net Change In Cash | 0 | 0 | 0 | 3,892 |
Free Cash Flow | -31,991 | -29,590 | -28,537 | -79,221 |
Cash | 7,557 | 51,181 | 50,895 | 70,495 |
Basic Shares | 162 | 75 | 48 | 30 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$21.32 |
2026-03-31 | -$0.13 |
2025-09-30 | -$53.50 |
2025-06-30 | -$65.94 |